In parallel, decreased levels of PD-L1 and TIM-3 gene expression were found (up to 60% of decrease with combination, p < 0.01) suggesting also CD8+ T cell activation, as part of the anti-tumor immune response, that was induced by cetuximab plus avelumab treatment (Fig. 4C). Here, CD8A is linked to neoplasm.